[Thallium-201 myocardial scintigraphy after intravenous infusion of adenosine triphosphate disodium: a preliminary study in the diagnosis of coronary artery disease]. 1991

S Kinoshita, and S Yamashita, and T Suzuki, and T Muramatsu, and M Ide, and Y Dohi, and K Nishimura, and T Miyamae
Second Department of Internal Medicine, Saitama Medical School, Japan.

The feasibility and safety of thallium-201 myocardial scintigraphy after the intravenous infusion of adenosine triphosphate disodium (ATP) (Adetphos, Kowa) were studied in eight patients with angina pectoris and/or old myocardial infarction. Coronary arteriography (CAG) was performed by the conventional method in all patients. ATP was infused for 5 min and thallium was injected at 3 min after the start of ATP infusion. ATP was given at 0.12 mg/min/kg in two patients (group A), 0.16 mg/min/kg in three patients (group B), 0.20 mg/min/kg in one patient (group C) and 0.28 mg/min/kg in two patients (group D). SPECT images were obtained at 10 min and 180 min after thallium injection. No significant hemodynamic changes were observed in group A and B. Severe hypotension was observed in group C and one member of group D. Chest pain was experienced by one patient in group A, two in group B, one in group C, and both of the two in group D. ST depression on the electrocardiogram (ECG) was documented in one patient each of groups B and C. In one group D patient, the study was discontinued because of complete atrioventricular block persistent for 5 beats. The correlation between thallium imaging and CAG was unclear in group A, reasonable in groups B and C, and obscure in group D because of side effects. None of the patients who developed side effects of ATP were administered sublingual nitroglycerin or intravenous aminophylline. Their symptoms or ECG changes improved spontaneously within 2 min and disappeared within 5 min after termination of infusion. In conclusion, the optimal ATP regimen for this purpose was considered to be a 5 min infusion at 0.16 mg/kg/min and this method was found to be feasible and safe.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D005240 Feasibility Studies Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project. Feasibility Study,Studies, Feasibility,Study, Feasibility
D005260 Female Females
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000255 Adenosine Triphosphate An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. ATP,Adenosine Triphosphate, Calcium Salt,Adenosine Triphosphate, Chromium Salt,Adenosine Triphosphate, Magnesium Salt,Adenosine Triphosphate, Manganese Salt,Adenylpyrophosphate,CaATP,CrATP,Manganese Adenosine Triphosphate,MgATP,MnATP,ATP-MgCl2,Adenosine Triphosphate, Chromium Ammonium Salt,Adenosine Triphosphate, Magnesium Chloride,Atriphos,Chromium Adenosine Triphosphate,Cr(H2O)4 ATP,Magnesium Adenosine Triphosphate,Striadyne,ATP MgCl2
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

S Kinoshita, and S Yamashita, and T Suzuki, and T Muramatsu, and M Ide, and Y Dohi, and K Nishimura, and T Miyamae
November 1995, Journal of the American College of Cardiology,
S Kinoshita, and S Yamashita, and T Suzuki, and T Muramatsu, and M Ide, and Y Dohi, and K Nishimura, and T Miyamae
May 1991, Journal of the American College of Cardiology,
S Kinoshita, and S Yamashita, and T Suzuki, and T Muramatsu, and M Ide, and Y Dohi, and K Nishimura, and T Miyamae
April 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
S Kinoshita, and S Yamashita, and T Suzuki, and T Muramatsu, and M Ide, and Y Dohi, and K Nishimura, and T Miyamae
December 1982, The American journal of cardiology,
S Kinoshita, and S Yamashita, and T Suzuki, and T Muramatsu, and M Ide, and Y Dohi, and K Nishimura, and T Miyamae
August 1994, Rontgenpraxis; Zeitschrift fur radiologische Technik,
S Kinoshita, and S Yamashita, and T Suzuki, and T Muramatsu, and M Ide, and Y Dohi, and K Nishimura, and T Miyamae
December 1987, Zeitschrift fur Kardiologie,
S Kinoshita, and S Yamashita, and T Suzuki, and T Muramatsu, and M Ide, and Y Dohi, and K Nishimura, and T Miyamae
June 1991, Archives des maladies du coeur et des vaisseaux,
S Kinoshita, and S Yamashita, and T Suzuki, and T Muramatsu, and M Ide, and Y Dohi, and K Nishimura, and T Miyamae
September 1998, Journal of cardiology,
S Kinoshita, and S Yamashita, and T Suzuki, and T Muramatsu, and M Ide, and Y Dohi, and K Nishimura, and T Miyamae
July 1991, American heart journal,
S Kinoshita, and S Yamashita, and T Suzuki, and T Muramatsu, and M Ide, and Y Dohi, and K Nishimura, and T Miyamae
January 2007, Journal of cardiology,
Copied contents to your clipboard!